Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEED: CTX vs EOX in Advanced Esophagogastric Adenocarcinoma
NCT02177552Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Jun 2014
- Primary completion
- Aug 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, docetaxel and capecitabine in esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (2 arms), sponsored by Rigshospitalet. Primary endpoint: Proportion of participants alive one year after randomisation at 1 year. Status: unknown.
02
Drugs
carboplatindocetaxelcapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02177552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177552.